Last reviewed · How we verify
MPDL3280A
MPDL3280A is a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 and B7-1, thereby releasing the brakes on anti-tumor immune responses.
MPDL3280A is a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 and B7-1, thereby releasing the brakes on anti-tumor immune responses. Used for Non-small cell lung cancer, Urothelial carcinoma, Gastric cancer.
At a glance
| Generic name | MPDL3280A |
|---|---|
| Also known as | atezolizumab, Atezolizumab, RG7446 |
| Sponsor | Clovis Oncology, Inc. |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting PD-L1, MPDL3280A prevents tumor cells from suppressing T-cell activation and proliferation. This allows the patient's immune system to recognize and attack cancer cells more effectively. The drug is designed to enhance anti-tumor immunity across multiple cancer types.
Approved indications
- Non-small cell lung cancer
- Urothelial carcinoma
- Gastric cancer
Common side effects
- Fatigue
- Decreased appetite
- Nausea
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
- Infusion reactions
Key clinical trials
- A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (PHASE2)
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (PHASE1, PHASE2)
- Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients (PHASE2)
- Iadademstat + SBRT With Atezo in ES-SCLC (PHASE1)
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung (PHASE2, PHASE3)
- A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
- A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MPDL3280A CI brief — competitive landscape report
- MPDL3280A updates RSS · CI watch RSS
- Clovis Oncology, Inc. portfolio CI